Results for this period
Full year1 July 2025 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Contributions came from the organic growth of existing hospitals, optimization of consultation prices, expansion of medical equipment, business scale expansion through M&A, and improved operating efficiency and cost synergies through group management. M&A-related expenses, PMI expenses and personnel recruitment expenses were incurred as upfront investments, and a gain on bargain purchase was recorded as extraordinary income.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 July 2025 to 30 June 2026 |
| Net Sales | ¥6,155 million (YoY +12.7%) |
| Operating profit | ¥1,127 million (YoY +23.9%) |
| Ordinary income | ¥1,131 million (YoY +24.6%) |
| Profit attributable to owners of the parent | ¥939 million (YoY +58.4%) |
| Net income per share | ¥124.88 |
| Operating Margin | Current fiscal year 18.3 % / Previous period 16.6 % |
| Equity ratio | End of the current fiscal period 54.7 / End of previous period 44.9 |
| Total assets | ¥6,768 million |
| Net assets | ¥3,718 million |
| Cash flows from operating activities | ¥1,124 million |
| Cash flows from investing activities | ¥-697 million |
| Cash flows from financing activities | ¥-514 million |
| Cash and cash equivalents at end of period | ¥808 million |
| Full-year earnings forecast | Net Sales ¥7,535 million (YoY +22.4%) / Operating profit ¥1,569 million (YoY +39.3%) / Ordinary income ¥1,569 million (YoY +38.7%) / Profit attributable to owners of the parent ¥1,005 million (YoY +7.0%) |
| Annual Dividend Forecast | 0.00 yen and sen → 26.00 yen and sen |
| Payout ratio | 19.6% |
| Shareholder Return Policy | Pay dividends from retained earnings based on a payout ratio of 20%. |
| Depreciation and amortization | ¥203,074 thousand |
| Impairment loss | ¥83,376 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥10,950 thousand, Gain on bargain purchase ¥227,452 thousand, Gain on step acquisition ¥12,913 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥897 thousand, Impairment Losses ¥83,376 thousand, Other ¥1,866 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 3 / Name of newly added company 飛鳥メディカル株式会社, 株式会社See, カルテック株式会社 / Excluded 0 / Excluded Company Name Not disclosed |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 7,974,000 Shares |
| Treasury Shares at Period-End | 409,400 Shares |
| Factors Behind Changes in Business Performance | Contributions came from the organic growth of existing hospitals, optimization of consultation prices, expansion of medical equipment, business scale expansion through M&A, and improved operating efficiency and cost synergies through group management. M&A-related expenses, PMI expenses and personnel recruitment expenses were incurred as upfront investments, and a gain on bargain purchase was recorded as extraordinary income. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Contributions came from the organic growth of existing hospitals, optimization of consultation prices, expansion of medical equipment, business scale expansion through M&A, and improved operating efficiency and cost synergies through group management. At the same time, upfront investments were made in M&A-related expenses, PMI expenses and personnel recruitment expenses, while a gain on bargain purchase arising from the acquisition of the business of カルテック株式会社 was recorded as extraordinary income.